Patents by Inventor Pingming Tang

Pingming Tang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250222116
    Abstract: A compound represented by formula (I), a stereoisomer, deuterated compound, solvate, pharmaceutically acceptable salt or co-crystal thereof, or a pharmaceutical composition containing them, and use of the compound as a PARP-1 inhibitor in the preparation of a drug for treating related diseases, each group in the formula (I) being as defined in the description.
    Type: Application
    Filed: October 21, 2022
    Publication date: July 10, 2025
    Inventors: Yao LI, Lei CHEN, Tiancheng HE, Pengxin GENG, Hao YAO, Haodong WANG, Linyong FANG, Gang HU, Pingming TANG, Yan YU, Chen ZHANG, Pangke YAN
  • Publication number: 20250215008
    Abstract: Disclosed are a compound represented by formula I, a stereoisomer, deuterated product or pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same, as well as a use thereof as a BRAF modulator in the preparation of a drug for the treatment of related diseases. Each group shown in formula (I) is as defined in the description.
    Type: Application
    Filed: July 19, 2023
    Publication date: July 3, 2025
    Inventors: Yao LI, Zongjun SHI, Lei CHEN, Yunpeng PEI, Tianbo SHU, Pengcheng WANG, Shaohui SHI, Linkun HE, Pingming TANG, Chen ZHANG, Pangke YAN
  • Publication number: 20250195485
    Abstract: A compound as represented by general formula (I) or a stereoisomer, a deuterated form, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a co-crystal thereof; an intermediate thereof and a preparation method therefor; and the use thereof in the preparation of a drug for treating diseases related to an integrin ?4?7 activity or expression level.
    Type: Application
    Filed: December 21, 2022
    Publication date: June 19, 2025
    Applicant: Xizang Haisco Pharmaceutical Co., Ltd.
    Inventors: Chen ZHANG, Ping HE, Haiqing HE, Yan YU, Pingming TANG, Zhaoli XUAN, Le WANG, Yao LI, Jia NI, Pangke YAN
  • Publication number: 20250171417
    Abstract: Disclosed are a compound as represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof and an intermediate thereof; and the use thereof m AR-related diseases such as cancer.
    Type: Application
    Filed: August 11, 2022
    Publication date: May 29, 2025
    Applicant: Xizang Haisco Pharmaceutical Co., Ltd.
    Inventors: Chen ZHANG, Yuting LIAO, Xiaogang CHEN, Jinxiong XU, Yan YU, Pingming TANG, Qiu GAO, Junbin ZHAO, Yupeng LI, Xinfan CHENG, Guozhi ZHU, Fei YE, Yao LI, Jia NI, Pangke YAN
  • Publication number: 20250171436
    Abstract: Disclosed in the present invention are a tricyclic fused heterocyclic compound having PDE3/4 dual inhibitory effect as represented by formula (1), and a stereoisomer, solvate, or pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating/preventing PDE3/4-mediated diseases, wherein each group in formula (1) is as defined in the description.
    Type: Application
    Filed: January 20, 2023
    Publication date: May 29, 2025
    Inventors: Yao Li, Guobiao Zhang, Xiaobo Zhang, Yaming Zhang, Shilin Huang, Linjie Yan, Pingming Tang, Yan Yu, Chen Zhang, Pangke Yan
  • Publication number: 20250145627
    Abstract: The present invention relates to a compound represented by general formula (I) or a stereoisomer, a tautomer, a deuterated substance, a solvate, a prodrug, a metabolite and a pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, and a use of the compound in METTL3-related diseases such as cancer.
    Type: Application
    Filed: February 14, 2023
    Publication date: May 8, 2025
    Inventors: Chen Zhang, Ming Lei, Tao Mou, Yan Yu, Pingming Tang, Yifei Meng, Guanglin Weng, Yao Li, Pangke Yan
  • Publication number: 20250084101
    Abstract: The present invention relates to a compound represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, and an intermediate thereof, and use thereof in IRAK4-related diseases such as an autoimmune disease, an inflammatory disease or cancer.
    Type: Application
    Filed: January 4, 2023
    Publication date: March 13, 2025
    Applicant: XIZANG HAISCO PHARMACEUTICAL CO., LTD.
    Inventors: Chen ZHANG, Yuting LIAO, Chenfei ZHAO, Yan YU, Pingming TANG, Junjie MA, Xiaogang CHEN, Shuai YUAN, Xinfan CHENG, Fei YE, Yao LI, Jia NI, Pangke YAN
  • Publication number: 20250059186
    Abstract: Disclosed are a tricyclic fused heterocyclic compound having a PDE3/4 dual inhibitory effect represented by formula (I), a stereoisomer, a solvate, or a pharmaceutically acceptable salt thereof, and the use thereof in the preparation of a drug for treating/preventing PDE3/4-mediated diseases. Each group in formula (I) is as defined in the description.
    Type: Application
    Filed: December 13, 2022
    Publication date: February 20, 2025
    Inventors: Yao Li, Guobiao Zhang, Xiaobo Zhang, Yaming Zhang, Linjie Yan, Pingming Tang, Yan Yu, Chen Zhang, Pangke Yan
  • Publication number: 20250034168
    Abstract: Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate, and eutectic or deuterated compound thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inhibitor in the preparation of a medication for treating related diseases. Each group in formula (I) is as defined in the description.
    Type: Application
    Filed: September 30, 2022
    Publication date: January 30, 2025
    Inventors: Yao LI, Haoliang ZHANG, Lei CHEN, Linyong FANG, Long WANG, Yufeng LUO, Pingming TANG, Yan YU, Chen Zhang, Pangke YAN
  • Publication number: 20250000988
    Abstract: Disclosed are a bicyclic peptide ligand having high affinity for Eph receptor tyrosine kinase A2 (EphA2), a drug conjugate containing the bicyclic peptide ligand and a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing same, and the use of the drug conjugate and the pharmaceutical composition in the preparation of a drug for preventing and/or treating EphA2 overexpressed disease.
    Type: Application
    Filed: October 14, 2022
    Publication date: January 2, 2025
    Applicant: Xizang Haisco Pharmaceutical Co., Ltd.
    Inventors: Yao LI, Lei CHEN, Haitao HUANG, Haodong WANG, Pingming TANG, Yan YU, Chen ZHANG, Pangke YAN
  • Publication number: 20240408085
    Abstract: A compound of general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or a co-crystal thereof, an intermediate thereof, and a use thereof in Bcl-2 family proteins-related diseases such as cancer.
    Type: Application
    Filed: September 1, 2022
    Publication date: December 12, 2024
    Inventors: Chen ZHANG, Yuting LIAO, Yonghua LU, Junbin ZHAO, Sijia ZOU, Yan YU, Pingming TANG, Qiu GAO, Xinfan CHENG, Fei YE, Yao LI, Jia NI, Pangke YAN
  • Publication number: 20240400586
    Abstract: Provided are a compound represented by formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate and eutectic or deuterated material thereof, or a pharmaceutical composition comprising same, and a use thereof as a PARP-1 inhibitor in the preparation of a drug for treating related diseases.
    Type: Application
    Filed: September 29, 2022
    Publication date: December 5, 2024
    Inventors: Yao LI, Wenjing WANG, Lei CHEN, Peng KANG, Chao FU, Tiancheng HE, Linyong FANG, Naicheng GUI, Pingming TANG, Yan YU, Chen ZHANG, Pangke YAN
  • Publication number: 20240391937
    Abstract: Disclosed are a compound as shown in formula (I), a stereoisomer, pharmaceutically acceptable salt, solvate, cocrystal or deuterated compound thereof, or a pharmaceutical composition containing same, and the use thereof as a PARP-1 inhibitor in the preparation of a drug for treating related diseases, wherein the definition of each group in formula (I) is as defined in the description.
    Type: Application
    Filed: September 30, 2022
    Publication date: November 28, 2024
    Inventors: Yao LI, Wenjing WANG, Lei CHEN, Peng KANG, Chao FU, Fengkai CHENG, Pingming TANG, Yan YU, Chen ZHANG, Pangke YAN
  • Publication number: 20240383917
    Abstract: Provided are a compound as shown in general formula (I), or a stereoisomer, deuterate, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, an intermediate thereof, a preparation method therefor, and the use thereof in the preparation of a drug for treating a disease associated with the activity or expression quantity of complement factor B.
    Type: Application
    Filed: August 18, 2022
    Publication date: November 21, 2024
    Applicant: Xizang Haisco Pharmaceutical Co., Ltd.
    Inventors: Chen ZHANG, Yuting LIAO, Guozhi ZHU, Dachao TANG, Yan YU, Pingming TANG, Xinfan CHENG, Yao LI, Jia NI, Pangke YAN
  • Publication number: 20240383874
    Abstract: Disclosed are a compound as represented by general formula (I) or a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, and an intermediate thereof, and the use thereof in AR or AR splicing mutant-related diseases such as cancer.
    Type: Application
    Filed: November 24, 2021
    Publication date: November 21, 2024
    Inventors: Chen Zhang, Yuting Liao, Fei Ye, Pingming Tang, Xiaogang Chen, Yonghua Lu, Qiu Gao, Yao Li, Jia Ni, Pangke Yan
  • Publication number: 20240368204
    Abstract: Disclosed is a compound of formula (I), and a stereoisomer, a pharmaceutically acceptable salt, a solvate, a co-crystal or a deuterated product thereof, or a pharmaceutical composition containing same, and the use thereof as a CD73 antagonist in the preparation of a drug for treating related diseases, wherein the definition of each group in formula (I) is consistent with the definition in the description.
    Type: Application
    Filed: May 10, 2022
    Publication date: November 7, 2024
    Inventors: Yao LI, Lei CHEN, Zongjun SHI, Gang HU, Pengxin GENG, Haodong WANG, Shaohui SHI, Yongli WANG, Pingming TANG, Yan YU, Chen ZHANG, Pangke YAN
  • Publication number: 20240343720
    Abstract: A compound of formula (I) and a stereoisomer, deuterated compound, solvate, prodrug, metabolite, pharmaceutically acceptable salt or co-crystal thereof, or a pharmaceutical composition containing same, and the use thereof as an AAK1 inhibitor in the preparation of a drug for treating related diseases.
    Type: Application
    Filed: July 14, 2022
    Publication date: October 17, 2024
    Inventors: Yao Li, Wenjing Wang, Zongjun Shi, Haoliang Zhang, Chenglong Du, Fengkai CHENG, Xin Liu, Xiaozhuan Zhang, Long Wang, Pingming Tang, Yan Yu, Chen Zhang, Pangke Yan
  • Publication number: 20240317736
    Abstract: Disclosed are a compound of formula (I), a stereoisomer, solvate, prodrug, metabolite, pharmaceutically acceptable salt, or eutectic thereof, or a pharmaceutical composition comprising same, and an application thereof as an ATX inhibitor in preparation of a drug for treating a related disease. Groups in formula (I) are as defined in the description.
    Type: Application
    Filed: November 4, 2021
    Publication date: September 26, 2024
    Inventors: Yao LI, Guobiao ZHANG, Xiaobo ZHANG, Pingming TANG, Yashu CHEN, Yan YU, Chen ZHANG, Pangke YAN
  • Publication number: 20240269298
    Abstract: Provided are the compound shown in general formula (I) or a stereoisomer, a deuterated compound, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt, or co-crystal thereof, an intermediate thereof, and a use thereof in EGFR-related diseases such as cancer.
    Type: Application
    Filed: April 29, 2022
    Publication date: August 15, 2024
    Inventors: Chen ZHANG, Jianmin WANG, Chenfei ZHAO, Guofei QIAN, Junjie MA, Zhenggang HUANG, Shuai YUAN, Anbang HUANG, Shaolong ZHENG, Kai LI, Yan YU, Fei YE, Pingming TANG, Yao LI, Jia NI, Pangke YAN
  • Publication number: 20240208932
    Abstract: The present invention relates to a compound as represented by formula (I) and a stereoisomer, solvate, deuterated compound or pharmaceutically acceptable salt or pharmaceutical composition thereof, and the use thereof in the preparation of a drug for treating/preventing ER-mediated diseases, wherein each group in formula (I) is as defined in the description.
    Type: Application
    Filed: July 14, 2022
    Publication date: June 27, 2024
    Inventors: Yao LI, Wenjing WANG, Zongjun SHI, Changwei SONG, Lei REN, Jie WANG, Pingming TANG, Yan YU, Chen ZHANG, Pangke YAN